The Oncology Institute, Inc. TOI Patient services — Direct costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s patient services — direct costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s patient services — direct costs?
- The Oncology Institute, Inc. (TOI) reported patient services — direct costs of $53.38M in Q1 2026.
- How has The Oncology Institute, Inc.'s patient services — direct costs changed year-over-year?
- The Oncology Institute, Inc.'s patient services — direct costs increased by 13.4% year-over-year, from $47.08M to $53.38M.
- What is the long-term trend for The Oncology Institute, Inc.'s patient services — direct costs?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s patient services — direct costs has grown at a 19.9% compound annual growth rate (CAGR), from $99.4M to $205.5M.
- What does patient services — direct costs mean?
- Encompasses the immediate costs incurred to provide oncology services, including pharmaceuticals, medical consumables, and direct labor costs for clinical staff. This metric is critical for calculating the gross margin and understanding the direct cost-to-revenue relationship in clinical service delivery.